Nektar Therapeutics announces press release on start of Phase 3 ZENITH AD program for rezpegaldesleukin in atopic dermatitis

Reuters2026/07/21 11:02

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Nektar published a press release announcing the start of its Phase 3 ZENITH AD program for rezpegaldesleukin in moderate-to-severe atopic dermatitis.
Two 510-patient registrational trials have begun; an additional 510-patient study in previously treated patients is slated to start in September.
Initial Phase 3 topline data are expected in mid-2028; a BLA submission is targeted for 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: SF03777) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nektar Therapeutics announces press release on start of Phase 3 ZENITH AD program for rezpegaldesleukin in atopic dermatitis

You may also like

Crypto prices